Perioperative Toripalimab Prolongs EFS in Stage III Lung Cancer
Adding an investigational anti-PD-1 drug to perioperative chemotherapy improved event-free survival (EFS) in patients with resectable, stage III non-small cell lung cancer (NSCLC), an interim analysis of a phase III study found. Among 404 patients receiving perioperative chemotherapy in the so-called Neotorch trial, the median investigator-assessed EFS was not reached in patients assigned to toripalimab, […]
Personalized Cancer Vaccine Boosts Recurrence-Free Survival in Melanoma
ORLANDO — Adding a personalized cancer vaccine to anti-PD-1 immunotherapy for resectable melanoma led to a 44% improvement in recurrence-free survival (RFS) versus immunotherapy alone, according to a study reported here. Patients who received the mRNA vaccine, derived from their own tumor, had an 18-month RFS of 78.6% as compared with 62.2% for patients who […]
PD-1 Inhibitor Boosts Survival in Treated Esophageal Cancer
Overall survival (OS) in previously treated esophageal cancer improved significantly with the anti-PD-1 drug tislelizumab compared to chemotherapy, a phase III, randomized trial showed. Patients randomized to tislelizumab had a median OS of 8.6 months as compared with 6.3 months for patients who received chemotherapy alone. A prespecified subgroup analysis of patients from Europe and […]